Biofrontera Application For Ameluz Usage In Basal Cell Carcinoma Treatment Received By FDA
Biofrontera Inc. -2.75% Pre
Biofrontera Inc. BFRI | 1.06 1.07 | -2.75% +0.94% Pre |
Biofrontera Application For Ameluz Usage In Basal Cell Carcinoma Treatment Received By FDA
